Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 2000 February; 82(4): 806–811.
PMCID: PMC2374380

Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study


The aim of the study was to evaluate efficacy and tolerance of epirubicin and gemcitabine as first-line chemotherapy in patients with advanced non-small-cell lung cancer. A phase I study was performed with the combination of escalating doses of epirubicin intravenously on day 1 and a fixed dose of gemcitabine on days 1 and 8 of a 21-day cycle. Eighteen patients were included in the phase I part of the study before the maximum tolerated dose was found. Dose-limiting toxicity was febrile neutropenia. The phase II part of the study was continued with epirubicin 100 mg m−2on day 1 and gemcitabine 1125 mg m−2on days 1 and 8 of a 21-day cycle. Forty-three chemotherapy-naive patients were included. The median age of the patients was 60 years (range 26–75). Most patients (74%) were in stage IV. Granulocytopenia CTC grade 4 occurred in 32.5% and thrombocytopenia grade 4 in 11.6% of cycles. Febrile neutropenia occurred in six patients. Non-haematological toxicity was mainly mucositis CTC grade 2 and 3 in 35% of patients. The tumour response rate was 49% (95% confidence interval (CI) 35–63%). The median survival time for the patients was 42 weeks (95% CI 13–69). © 2000 Cancer Research Campaign

Keywords: non-small-cell lung cancer, chemotherapy, epirubicin, gemcitabine

Full Text

The Full Text of this article is available as a PDF (69K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol. 1994 Aug;12(8):1535–1540. [PubMed]
  • Abratt RP, Bezwoda WR, Goedhals L, Hacking DJ. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol. 1997 Feb;15(2):744–749. [PubMed]
  • Antón A, Díaz-Fernández N, González Larriba JL, Vadell C, Masutti B, Montalar J, Barneto I, Artal A, Rosell R. Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC). Lung Cancer. 1998 Nov;22(2):139–148. [PubMed]
  • Bakker M, Groen HJ, Smit EF, Smeets J, Riggi M, Postmus PE. Phase I study of high-dose epirubicin and vinorelbine in previously untreated non-small-cell lung cancer stage IIIB-IV. Br J Cancer. 1995 Dec;72(6):1547–1550. [PMC free article] [PubMed]
  • Brocato N, Bruno MF, Araujo CE, Cervellino JC, Pirisi C, Temperley G, Sparrow C, Savulsky C, Balbiani LR. Treatment of non-small cell lung cancer with ifosfamide (IFO)+ 4'-epiadriamycin (EPI)+platinum vs. IFO+EPI: a GETLAC Study. Grupo de Estudio y Tratamiento Latinoamericano del Cáncer Study. Oncology. 1995 Jan-Feb;52(1):24–31. [PubMed]
  • Bunn PA., Jr Review of therapeutic trials of carboplatin in lung cancer. Semin Oncol. 1989 Apr;16(2 Suppl 5):27–33. [PubMed]
  • Cardenal F, López-Cabrerizo MP, Antón A, Alberola V, Massuti B, Carrato A, Barneto I, Lomas M, García M, Lianes P, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 1999 Jan;17(1):12–18. [PubMed]
  • Crinò L, Scagliotti G, Marangolo M, Figoli F, Clerici M, De Marinis F, Salvati F, Cruciani G, Dogliotti L, Pucci F, et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 1997 Jan;15(1):297–303. [PubMed]
  • Feld R, Wierzbicki R, Walde PL, Shepherd FA, Evans WK, Gupta S, Shannon P, Lassus M. Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer. J Clin Oncol. 1992 Feb;10(2):297–303. [PubMed]
  • Gatzemeier U, Shepherd FA, Le Chevalier T, Weynants P, Cottier B, Groen HJ, Rosso R, Mattson K, Cortes-Funes H, Tonato M, et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer. 1996 Feb;32A(2):243–248. [PubMed]
  • Georgoulias V, Kouroussis C, Androulakis N, Kakolyris S, Dimopoulos MA, Papadakis E, Bouros D, Apostolopoulou F, Papadimitriou C, Agelidou A, et al. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial. J Clin Oncol. 1999 Mar;17(3):914–920. [PubMed]
  • Grant SC, Gralla RJ, Kris MG, Orazem J, Kitsis EA. Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients. J Clin Oncol. 1992 Mar;10(3):484–498. [PubMed]
  • Launchbury AP, Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev. 1993 Jul;19(3):197–228. [PubMed]
  • Lilenbaum RC, Langenberg P, Dickersin K. Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response, toxicity, and survival. Cancer. 1998 Jan 1;82(1):116–126. [PubMed]
  • Marino P, Pampallona S, Preatoni A, Cantoni A, Invernizzi F. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest. 1994 Sep;106(3):861–865. [PubMed]
  • Plosker GL, Faulds D. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy. Drugs. 1993 May;45(5):788–856. [PubMed]
  • Canellos GP. Current strategies for early Hodgkin's disease. Ann Oncol. 1996;7 (Suppl 4):91–93. [PubMed]
  • Smit EF, Berendsen HH, Piers DA, Smeets J, Riva A, Postmus PE. A phase II study of high dose epirubicin in unresectable non small cell lung cancer. Br J Cancer. 1992 Mar;65(3):405–408. [PMC free article] [PubMed]
  • Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, Kaasa S, Pater JL, Quoix E, Rapp E, et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet. 1993 Jul 3;342(8862):19–21. [PubMed]
  • Wilkes JD. Prevention and treatment of oral mucositis following cancer chemotherapy. Semin Oncol. 1998 Oct;25(5):538–551. [PubMed]
  • Wils J, Utama I, Sala L, Smeets J, Riva A. Phase II study of high-dose epirubicin in non-small cell lung cancer. Eur J Cancer. 1990;26(11-12):1140–1141. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK